Mark Altmeyer is the founder of Arvelle Therapeutics. Arvelle Therapeutics has raised $100M in total funding. Latest round: Series A.
Mark Altmeyer is the Founder and CEO of Arvelle Therapeutics, a specialty neurology company focused on treating treatment-refractory epilepsy with its lead compound Cenobamate in Europe. He moved from big pharma into startups, highlighting his focus on data-driven compound selection and forming efficient teams in biotech.
Full founder directory · Investor directory · Company funding database · Fundraising library
The Startup Fundraising Platform
Raise funds for your startup
Find the right investors and get real replies — instantly, powered by AI.
Takes 30 seconds · No credit card · Cancel anytime
Slide-by-slide guide